Phase Ib/II Clinical Trial of TY-302 and Abiraterone Acetate in mCRPC
/in Clinical Trial, Phase 1, Phase 2/by MaxFDA Clears First-in-Human Trial of NSD2 Inhibitor in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1: SYN608 Targets DNA Repair in HRR-Deficient Prostate and Other Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxLow-Dose Abiraterone Acetate: Phase 1 Trial Looks Very Promising
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025